IIP-Technologies GmbH, on behalf of its parent company Intelligent Medical Implants AG (“IMI”) (www.intmedimplants.com), announced today that results of a limited clinical study related to its ongoing Early Human Trial will be presented from the podium tomorrow at The Eye and The Chip: World Congress on Artificial Vision in Detroit. The results to be presented will demonstrate that IMI’s patented, first-generation Learning Retinal Implant(TM) enabled blind patients to see light--as well as simple patterns--via a wireless transmission of data and energy. This represented the first time in the history of the development of artificial vision that completely wireless transmission of data and energy into an implant in the eye of long-time blind persons has resulted in pattern recognition.
